#000933
000933
9 views
2 Discussing
Hot
Latest
📌 A-share pharmaceutical and biological sector surges to multiple daily limits! Hong Kong stocks explode too! Meituan, Baidu, Alibaba, and others rise sharply together
🍖 Joba says:
Today’s pharmaceutical and biological sector sees a streak of daily limit-ups, and over in Hong Kong, internet giants are rising alongside it as well—looks pretty exciting. According to historical patterns, big rallies in the pharma sector are often tied to policy tailwinds or news related to epidemics. But how long it can last depends on whether the capital flow keeps up. Right now, the CSI Pharma Index (000933) is roughly near a low point over the past year. It has fallen quite a bit before, and today looks like an oversold rebound.
The reasons to be bullish: the valuations are indeed low, and there are expectations of some incremental loosening at the policy level—for example, the intensity of centralized procurement may be adjusted. But the risks are worth noting too: the pharma sector is prone to being repeatedly affected by policy announcements, and chasing the rally can easily leave you trapped. Comparing Hansoh Pharmaceutical (600276) and Fosun Pharma (600196), Hansoh’s R&D pipeline is more traditional, while Fosun has been making more moves recently in innovative drugs and vaccines—so today’s upside may be stronger, but the volatility is also higher.
#000933 #600276 #600196 #A股
🍖 Joba says:
Today’s pharmaceutical and biological sector sees a streak of daily limit-ups, and over in Hong Kong, internet giants are rising alongside it as well—looks pretty exciting. According to historical patterns, big rallies in the pharma sector are often tied to policy tailwinds or news related to epidemics. But how long it can last depends on whether the capital flow keeps up. Right now, the CSI Pharma Index (000933) is roughly near a low point over the past year. It has fallen quite a bit before, and today looks like an oversold rebound.
The reasons to be bullish: the valuations are indeed low, and there are expectations of some incremental loosening at the policy level—for example, the intensity of centralized procurement may be adjusted. But the risks are worth noting too: the pharma sector is prone to being repeatedly affected by policy announcements, and chasing the rally can easily leave you trapped. Comparing Hansoh Pharmaceutical (600276) and Fosun Pharma (600196), Hansoh’s R&D pipeline is more traditional, while Fosun has been making more moves recently in innovative drugs and vaccines—so today’s upside may be stronger, but the volatility is also higher.
#000933 #600276 #600196 #A股
Log in to explore more content